Filtered By:
Source: Diabetes Care
Condition: Diabetes

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 76 results found since Jan 2013.

Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes
CONCLUSIONS The absolute risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception is low. Highly effective, intrauterine and subdermal contraceptives are excellent options for women with diabetes who hope to avoid the teratogenic effects of hyperglycemia by carefully planning their pregnancies.
Source: Diabetes Care - January 19, 2017 Category: Endocrinology Authors: OBrien, S. H.; Koch, T.; Vesely, S. K.; Schwarz, E. B. Tags: Epidemiology/Health Services Research Source Type: research

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
CONCLUSIONS Among older patients with well-controlled type 2 diabetes and cardiovascular disease, sitagliptin had neutral effects on cardiovascular risk and raised no significant safety concerns.
Source: Diabetes Care - March 20, 2017 Category: Endocrinology Authors: Bethel, M. A.; Engel, S. S.; Green, J. B.; Huang, Z.; Josse, R. G.; Kaufman, K. D.; Standl, E.; Suryawanshi, S.; Van de Werf, F.; McGuire, D. K.; Peterson, E. D.; Holman, R. R.; for the TECOS Study Group Tags: Emerging Science and Concepts for Management of Diabetes and Aging Source Type: research

Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry
CONCLUSIONS The presence of diabetes markedly increases the risk of 1-year adverse clinical outcomes in outpatients with CHF independent of multiple common risk factors. More effective and personalized treatment for diabetes should be considered in this particularly high-risk patient population.
Source: Diabetes Care - April 20, 2017 Category: Endocrinology Authors: Dauriz, M.; Targher, G.; Laroche, C.; Temporelli, P. L.; Ferrari, R.; Anker, S.; Coats, A.; Filippatos, G.; Crespo-Leiro, M.; Mebazaa, A.; Piepoli, M. F.; Maggioni, A. P.; Tavazzi, L.; for the ESC-HFA Heart Failure Long-Term Registry Tags: Cardiovascular and Metabolic Risk Source Type: research

Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study
CONCLUSIONS The presence of major ECG abnormalities is associated with an increased risk of CVD in patients with type 1 diabetes. This suggests a potential role for ECG screening in patients with type 1 diabetes to identify individuals at risk for CVD.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Soliman, E. Z.; Backlund, J.-Y. C.; Bebu, I.; Orchard, T. J.; Zinman, B.; Lachin, J. M.; the DCCT/EDIC Research Group Tags: Cardiovascular and Metabolic Risk Source Type: research

Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators
CONCLUSIONS A large initial HbA1c reduction and achievement of low HbA1c levels within 6 months after metformin initiation are associated with a lower risk of cardiovascular events and death in patients with type 2 diabetes.
Source: Diabetes Care - May 22, 2017 Category: Endocrinology Authors: Svensson, E.; Baggesen, L. M.; Johnsen, S. P.; Pedersen, L.; Norrelund, H.; Buhl, E. S.; Haase, C. L.; Thomsen, R. W. Tags: Cardiovascular and Metabolic Risk Source Type: research

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively. The EMPA-REG OUTCOME, ...
Source: Diabetes Care - June 21, 2017 Category: Endocrinology Authors: Abdul-Ghani, M.; DeFronzo, R. A.; Del Prato, S.; Chilton, R.; Singh, R.; Ryder, R. E. J. Tags: Epidemiology-Diabetes Complications Perspectives in Care Source Type: research

Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1{alpha}1-67 in Patients With Type 2 Diabetes
CONCLUSIONS DPP-4 inhibition promotes a distal tubular natriuresis in conjunction with increased levels of intact SDF-1α1-67. Because of the distal location of the natriuretic effect, DPP-4 inhibition does not affect tubuloglomerular feedback or impair renal hemodynamic function, findings relevant to using DPP-4 inhibitors for treating type 2 diabetes.
Source: Diabetes Care - July 21, 2017 Category: Endocrinology Authors: Lovshin, J. A.; Rajasekeran, H.; Lytvyn, Y.; Lovblom, L. E.; Khan, S.; Alemu, R.; Locke, A.; Lai, V.; He, H.; Hittle, L.; Wang, W.; Drucker, D. J.; Cherney, D. Z. I. Tags: Complications-Nephropathy-Clinical and Translational Research Pathophysiology/Complications Source Type: research

The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology
CONCLUSIONS The 2h-PG, in contrast to FPG and HbA1c, provides significant prognostic information regarding cardiovascular events in patients with CAD. Furthermore, elevated 2h-PG and HbA1c are significant prognostic indicators of an increased risk of incident diabetes.
Source: Diabetes Care - August 22, 2017 Category: Endocrinology Authors: Shahim, B.; De Bacquer, D.; De Backer, G.; Gyberg, V.; Kotseva, K.; Mellbin, L.; Schnell, O.; Tuomilehto, J.; Wood, D.; Ryden, L. Tags: Epidemiology-Clinical-Diagnosis and Screening Cardiovascular and Metabolic Risk Source Type: research

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Clarke, G. D.; Solis-Herrera, C.; Molina-Wilkins, M.; Martinez, S.; Merovci, A.; Cersosimo, E.; Chilton, R. J.; Iozzo, P.; Gastaldelli, A.; Abdul-Ghani, M.; DeFronzo, R. A. Tags: Epidemiology-Diabetes Complications Pathophysiology/Complications Source Type: research

Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes
CONCLUSIONS We found that discrete FBG trajectories were significantly associated with subsequent risk of MI in individuals without diabetes. These observations suggest that long-term trajectories of FBG may be important for risk prediction of MI and possibly other macrovascular diseases.
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Jin, C.; Chen, S.; Vaidya, A.; Wu, Y.; Wu, Z.; Hu, F. B.; Kris-Etherton, P.; Wu, S.; Gao, X. Tags: Epidemiology-Cardiovascular Disease Cardiovascular and Metabolic Risk Source Type: research

30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-term Patterns of Glycemic Control
CONCLUSIONSThese risk factor differences suggest that pathways to CVD may differ by glycemic control, potentially resulting in important implications for prognosis in type 1 diabetes.
Source: Diabetes Care - November 15, 2021 Category: Endocrinology Source Type: research

Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study
CONCLUSIONSA history of GDM was associated with increased risks of overall and specific CVDs. Increased risks were partly explained by subsequent type 2 diabetes, and the need to identify other pathways remains important. Continuous monitoring of women with a history of GDM, especially those with prepregnancy obesity or maternal history of CVD, may provide better opportunities to reduce their cardiovascular risk.
Source: Diabetes Care - November 11, 2021 Category: Endocrinology Source Type: research

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
CONCLUSIONSIn patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.
Source: Diabetes Care - October 29, 2021 Category: Endocrinology Source Type: research

Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study
CONCLUSIONSMild degrees of hyperglycemia and presence of comorbidities were associated with incident dementia. Intervention during the prodromal stage of a chronic disease (e.g., prediabetes) could be considered for dementia prevention.
Source: Diabetes Care - October 28, 2021 Category: Endocrinology Source Type: research

Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
CONCLUSIONSOur findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.
Source: Diabetes Care - March 21, 2023 Category: Endocrinology Source Type: research